2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs

US10435396B2 · kind B2 · utility

Assignee

• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Ulrich Bothe · Berlin, DE
• Holger Siebeneicher · Berlin, DE
• Nicole SCHMIDT · San Francisco, US
• Judith Günther · Berlin, DE
• Holger STEUBER · Berlin, DE
• Ulf Bömer · Glienicke, DE
• Martin Lange · Berlin, DE
• Reinhard NUBBEMEYER · Berlin, DE
• Nicholas Charles Ray · Witham, GB
• Pascal Pierre Alexandre Savy · Harlow, GB

Key dates

• Filing date: Feb 28, 2017
• Grant date: Oct 8, 2019
• Expiry date: Feb 28, 2037

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.